Clinical Trials Logo

NSCLC clinical trials

View clinical trials related to NSCLC.

Filter by:

NCT ID: NCT06315010 Not yet recruiting - NSCLC Clinical Trials

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

REPOSE
Start date: August 2024
Phase: Phase 2
Study type: Interventional

REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.

NCT ID: NCT06221670 Not yet recruiting - NSCLC Clinical Trials

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, open, single-center, single-arm phase II clinical study in non-small cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK fusion variants identified in the central laboratory. To evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.

NCT ID: NCT06218069 Not yet recruiting - NSCLC Clinical Trials

Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor

IMPRINT
Start date: August 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This study investigates whether a single subcutaneous administration of anti-PD-1 antibody can induce CD8+ T-cell tumor-infiltration that can be non-invasively monitored with [89Zr]crefmirlimab berdoxam PET imaging as an imaging biomarker.

NCT ID: NCT06182761 Not yet recruiting - NSCLC Clinical Trials

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

WUKONG-9
Start date: January 2024
Phase: Phase 2
Study type: Interventional

The study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with Anlotinib in patients whose disease has progressed following first-line EGFR-TKIs treatment.

NCT ID: NCT06054191 Not yet recruiting - NSCLC Clinical Trials

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase II, two parallel group study assessing the efficacy and safety of neoadjuvant and adjuvant targeted therapy in patients with stage IB-IIIA NSCLC harboring BRAF V600 or MET exon14 mutations.

NCT ID: NCT06029816 Not yet recruiting - NSCLC Clinical Trials

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations

CVL009-2001
Start date: November 20, 2023
Phase: Phase 2
Study type: Interventional

Single-arm, open-label, multicenter phase II clinical study

NCT ID: NCT05991193 Not yet recruiting - NSCLC Clinical Trials

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

Start date: December 29, 2023
Phase:
Study type: Observational

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

NCT ID: NCT05988697 Not yet recruiting - Advanced Cancer Clinical Trials

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Start date: November 1, 2023
Phase:
Study type: Observational

The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)

NCT ID: NCT05932264 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Start date: July 2023
Phase: Phase 2
Study type: Interventional

This is a phase 2, open-label study to evaluate the efficacy and safety of combination of Apatinib and Fluzoparib with or without Adebrelimab in previously-treated TP53-mutant advanced non-small cell lung cancer.

NCT ID: NCT05909137 Not yet recruiting - NSCLC Clinical Trials

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

Start date: September 2024
Phase:
Study type: Observational

Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC. Our preliminary study confirmed that the treatment of CTV-omitted IMRT regimen did not compromise the PFS or OS and significantly reduced the incidence of severe radiation pneumonia and radiation esophagitis. The purpose of this study was to observe the role of radiotherapy modalities that omit CTV in the context of immunotherapy for NSCLC.